Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Individual dosing of ASA prophylaxis by controlling platelet aggregation
Autore:
Syrbe, G; Redlich, H; Weidlich, B; Ludwig, J; Kopitzsch, S; Gockeritz, A; Herzog, K;
Indirizzi:
Dist Hosp Stadtroda Thuringia, Dept Internal Med, Stradtroda, Thuringen, Germany Dist Hosp Stadtroda Thuringia Stradtroda Thuringen Germany ngen, Germany Dist Hosp Stadtroda Thuringia, Clin Lab, Stradtroda, Thuringen, Germany Dist Hosp Stadtroda Thuringia Stradtroda Thuringen Germany ngen, Germany
Titolo Testata:
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
fascicolo: 3, volume: 7, anno: 2001,
pagine: 209 - 213
SICI:
1076-0296(200107)7:3<209:IDOAPB>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMERICAN-HEART-ASSOCIATION; ACUTE MYOCARDIAL-INFARCTION; HEALTH-CARE PROFESSIONALS; STROKE COUNCIL; ASPIRIN; STATEMENT; ACETYLATION; INHIBITION; MECHANISM; TRIAL;
Keywords:
platelet aggregation; acetylsalicyclic acid; slope; primary and secondary prevention; cardiovascular diseases; diabetes mellitus;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Syrbe, G Landesfachkrankenhaus Neurol & Psychiat Stadtroda, Bahnhofstr 1A,D-07646 Stadtroda, Thuringen, Germany Landesfachkrankenhaus Neurol & Psychiat Stadtroda Bahnhofstr 1A Stadtroda Thuringen Germany D-07646
Citazione:
G. Syrbe et al., "Individual dosing of ASA prophylaxis by controlling platelet aggregation", CL APPL T-H, 7(3), 2001, pp. 209-213

Abstract

Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day wassufficient to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic acid treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 07:11:43